Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003225 · ClinicalTrials.gov registry record · Phase 1
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00003225 is a Phase 1 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 23 participants.
The verdict
NCT00003225, a Phase 1 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus irinotecan in treating patients with metastatic colorectal cancer.
Interventions
- DRUG irinotecan hydrochloride
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 1997-07 |
| Est. Completion | 2001-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003225
The ClinicalTrials.gov registry entry for NCT00003225 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which irinotecan hydrochloride is the first listed.
NCT00003225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003225 about?
NCT00003225 is a clinical study titled "Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus irinotecan in treating patients with metastatic colorectal cancer.
What is the current status of trial NCT00003225?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 1997-07. Estimated completion is 2001-06.
What interventions are being tested in trial NCT00003225?
The interventions under investigation include: irinotecan hydrochloride (DRUG), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00003225?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.